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Tamoxifen reduces breast cancer incidence in women at increased risk, but may cause side-effects. 
We examined women’s knowledge of tamoxifen’s potential harms and benefits, and the extent to 
which knowledge reflects subjective judgements of awareness and decision quality. After a hospital 
appointment, 408 (55.7%) women at increased risk of breast cancer completed a survey assessing 
objective knowledge about the potential benefit (risk reduction) and harms (endometrial cancer, 
thromboembolic events, and menopausal side-effects) of tamoxifen, and subjective tamoxifen 
knowledge and decisional quality. 258 (63.2%) completed a 3-month follow-up survey.  15.7% of 
participants recognised the potential benefit and three major harms of using tamoxifen. These 
women were more likely to have degree level education (vs. below degree level) (OR=2.24, 95%CI: 
1.11-4.55) and good numeracy (vs. poor numeracy) (OR=5.91, 95%CI: 1.33-26.19). Tamoxifen uptake 
was higher in women who recognised all harms and benefits (vs. not recognising) (OR=2.47, 95%CI: 
0.94–6.54). 65.8% of tamoxifen users were unaware of its potential benefit and harms. Most (87.1%) 
women reported feeling informed about tamoxifen, and subjective decisional quality was high 
(Mean [SD], 17.03 [1.87], out of 18). Knowledge regarding the potential harms and benefit of 
tamoxifen is low in women considering prevention therapy, and they may need additional support to 




Breast cancer affects over 54,000 UK women each year (1). Women with first- and second-degree 
relatives with breast cancer are at increased risk of developing the disease (2). Breast cancer risk can 
be calculated using established models (3). The National Institute of Health and Care Excellence 
(NICE) considers women with a lifetime risk of breast cancer of 17-30% to be at moderate risk, and 
those exceeding this level to be at high risk (4). Women within these categories are eligible for early 
mammographic screening, and have the option of using medications for preventive therapy.  
 
Tamoxifen can reduce breast cancer risk among this population by at least 30% (5,6). However, 
tamoxifen users may experience adverse effects of the medication. For example, tamoxifen 
increases the risk of gynaecological and vasomotor symptoms, thromboembolic events and 
endometrial cancer (5,7–9). The majority of side-effects start within 12-months of initiation, but can 
occur throughout treatment (7,8). 
 
There is widespread reluctance to use preventive therapy among patients, with fewer than one in 7 
eligible women initiating therapy after it has been offered (10–12). Lack of information on 
chemoprevention has been reported by patients as one barrier to initiation (13,14). Healthcare 
professionals in primary and secondary care have expressed concern about their ability to discuss 
the harms and benefits with patients (15). A national survey of United Kingdom (UK) general 
practitioners (GPs) indicated just over half were aware tamoxifen could reduce breast cancer risk in 
healthy women, and only 42% felt comfortable discussing its harms and benefits (16). Women may 
feel dissatisfied with the support they receive from healthcare professionals, and could leave 





Supporting women to make an informed decision should be a goal of a clinical appointment, as 
outlined in shared decision-making frameworks both in the UK (17) and in the US (18). Assessing 
objective patient knowledge is one approach to evaluating the quality of decisions occurring in this 
setting. However, it is also important to consider subjective methods, such as the extent to which 
people feel informed and satisfied with their involvement in the decision-making process (19,20). 
Subjective knowledge assessments may reflect perceived adequacy of the information provided (20), 
but are often only weakly associated with objective knowledge (21). To date, no studies have 
included subjective assessments of decision quality in women considering preventive therapy, 
indicating that aspects of informed decision-making have not been fully considered. In women 
making breast cancer treatment decisions, clinician communication style (22,23) and receipt of a 
decision support tool (24) were related to subjective decision quality, and ethnic minority groups 
were more likely to report lower quality decision-making experiences (25). 
 
In this study we assessed objective knowledge about the potential harms and benefits of tamoxifen 
in women at increased risk of breast cancer, and also women’s subjective assessments of their 
knowledge and the quality of their decision about chemoprevention. We examined the socio-
demographic, health-service and psychological factors associated with objective knowledge about 
tamoxifen, and the extent to which knowledge was related to tamoxifen uptake and subjective 
decisional quality. 
 
Material and methods 
Ethics 
Ethical approval was awarded by the National Research Ethics Service Committee North West—
Preston (14/NW/1408). All procedures performed in studies involving human participants were in 
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accordance with the ethical standards of the institutional and/or national research committee and 
with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. 
 
Context 
Recruitment took place between September 2015 and December 2016 in hospital outpatient clinic 
settings. At the time these data were collected tamoxifen was included within the 2013 National 
Institute for Health and Care Excellence (NICE) clinical guideline CG164 for the management and care 
of women with a family history of breast cancer (26). However, at this point tamoxifen was not 
licenced for this indication by the Medicines and Healthcare products Regulatory Agency (MHRA), 
meaning that clinicians wishing to prescribe the drug would have to do so ‘off-label’.  
 
Women who present to primary care due to concerns about their breast cancer risk are referred to 
secondary care if their GP believes they are likely to meet NICE criteria for moderate or high breast 
cancer risk (4). During the secondary care appointment, women are asked about the age and onset 
of cancers within their family to produce a pedigree. This information is used to assess their risk as 
‘population level’, ‘moderate’ or ‘high’ according to NICE thresholds (4). This phrasing is used with 
patients, unless they specifically ask for a percentage risk estimate. If a numerical risk estimate is 
requested, they will be told the following risk estimates: population (<17% lifetime risk), moderate 
(17-29% lifetime risk), high (≥30% lifetime risk). The topic of tamoxifen will be discussed with women 
who are at moderate or high risk. Women who are interested in using tamoxifen for primary 
prevention will generally be required to book a GP appointment, where the GP will consider 
prescribing the drug, in consultation with a secondary clinician. However, in some circumstances the 
prescription could be initiated in secondary care by a clinical geneticist, oncologist or surgeon, and 




Four types of clinic in secondary and tertiary care were used to identify women at increased risk of 
breast cancer: family history clinics (n=12), breast clinics (n=4), clinical genetics centres (n=3), and a 




Following their appointment, women were approached by a research nurse or a healthcare 
professional to discuss the study. Women were eligible if they were aged 18 years or older, spoke 
English, had discussed preventive therapy with a healthcare professional, were assessed within their 
clinical appointment as having a ‘moderately high’ or ‘high’ risk of breast cancer according to NICE 
guidelines (4); and had no known contraindications for tamoxifen use. The study protocol did not 
require healthcare professionals to change any aspect of the discussion they would typically have 
with patients, including how tamoxifen was presented during the consultation. Women were 
excluded if they were unable to consent, read English, or had a previous diagnosis of breast cancer. 
 
Measures 
Women were invited to complete a baseline survey containing measures of knowledge, healthcare 
professional satisfaction, and information provision. Women returning baseline questionnaires were 
sent a follow-up questionnaire at 3-months containing a measure of subjective decisional quality and 
an item assessing their decision about uptake of tamoxifen for preventive therapy. Length of follow-
up was decided on the basis that this was a reasonable amount of time to consider the harms and 
benefits of tamoxifen, and speak with a GP about obtaining a prescription. A reminder postcard was 
sent to participants who did not respond to either the baseline or 3-month questionnaire within 2 
7 
 
weeks. A reminder questionnaire was sent to participants who did not return either the baseline or 
3-month questionnaire within 2 weeks of the reminder postcard. The full baseline survey and follow 
up survey are available here: https://osf.io/mqz9y/. 
 
Objective knowledge about tamoxifen  
The items assessing objective knowledge were adapted from a 6-item questionnaire used previously 
(27). Knowledge was assessed by listing three potential harms of using tamoxifen for preventive 
therapy (endometrial cancer, menopausal symptoms, blood clotting) and one potential benefit 
(breast cancer). For each potential harm and benefit, women were asked ‘Who is more likely to 
experience the following…?’ Responses were: ‘Women who take tamoxifen’, ‘Women who do not 
take tamoxifen’, ‘Both groups are equally likely’, and ‘Unsure’. The correct response for the three 
potential harms was ‘Women who take tamoxifen’, and the correct response for the potential 
benefit was ‘Women who do not take tamoxifen’. All other responses were marked as incorrect. 
Women who correctly answered all three potential harms and the potential benefit of using 
tamoxifen were classified as having good knowledge in the main analysis. Women who had missing 
data on any of the four items were excluded from the analysis (n = 25). The Kuder-Richardson 
reliability coefficient (KR-20) for this 4-item scale was 0.65.  
 
Subjective knowledge about tamoxifen 
A single item assessed participants’ current perceived knowledge about tamoxifen following their 
appointment in secondary care: ‘How informed do you feel about tamoxifen and its use by women 
at increased risk of breast cancer?’ Responses were: ‘Not very informed at all’ (=1), ‘Quite 
uninformed’ (=2), ‘Quite well informed’ (=3), and ‘Very well informed’ (=4). We wanted to examine 
the group of women who reported feeling strongly uninformed, therefore participants who 
responded ‘Not very informed at all’ were coded as being uninformed. All other responses were 




Healthcare professional satisfaction 
The validated genetic counselling satisfaction scale was used (28). This 6-item scale assesses patient 
satisfaction with the appointment and healthcare professional. In this context, participants assessed 
their satisfaction with their appointment in secondary care and the healthcare professional they saw 
during that visit (e.g. family history physician, genetics counsellor, clinical geneticist, surgeon, nurse 
specialist). Example items include: ‘The clinician considered any stress I was facing’, ‘The clinician 
was concerned about my wellbeing’, and ‘The appointment was helpful to me’. Each item was 
scored on a 4-point scale (‘strongly disagree’ [=1] to ‘strongly agree’ [=4]). Items were summed to 
create a scale score ranging from 6 – 24, with higher scores indicating stronger healthcare 
professional satisfaction. Cronbach’s alpha for the total scale was 0.93.  
 
Information provision 
A single item assessed whether women reported receiving information about preventive therapy 
during their appointment: ‘During your hospital appointment, did the clinician give you a leaflet 
about tamoxifen? (‘Yes’, ‘No’, and ‘Unsure’). No and unsure responses were combined, with missing 
data for this item also included in this category.  
 
Subjective decision quality 
The brief measure of subjective decision quality for breast cancer treatment was adapted for the 
preventive therapy setting and used in the 3-month follow-up questionnaire (20). This scale assesses 
six dimensions of subjective decision quality: ‘How “right for you” was your decision about 
tamoxifen’ (fit) (‘not at all right for me’ [=1]; ‘neither right or wrong’ [=2]; ‘completely right for me’ 
[=3]); ‘How much information did you have for your decision about tamoxifen’ (adequacy of 
information) (‘not enough information’ [=1]; ‘enough information’ [=2]; ‘too much information [=3]); 
‘How much time did you have for your decision about tamoxifen’ (adequacy of time) (‘not enough 
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time’ [=1]; ‘just right’ [=2]; ‘too much time [=3]); ‘How much involvement did you have in your 
decision about tamoxifen’ (adequacy of involvement) (‘not enough involvement’ [=1]; ‘just right 
[=2]’; ‘too much involvement’ [=3]); ‘How much regret do you have with regard to your decision 
about tamoxifen?’ (regret) (‘no regret’ [=1]; ‘some regret’ [=2]; a lot of regret [=3]); ‘How satisfied 
are you with the decision you made about tamoxifen’ (satisfaction) (‘not at all satisfied [=1]; 
‘somewhat satisfied’ [=2]; ‘totally satisfied’ [=3]). Each item included a ‘still deciding’ response (=4). 
As the quality of decisions cannot be assessed in people who have not finalised their decision, we 
restricted our analysis of this outcome to the sub-sample of women who reported that they had 
made a decision (56.8%, 146/257). Responses were re-coded in line with the original guidelines (20). 
A single scale score was calculated (ranging from 6 to 18), with higher scores indicating higher 
subjective decision quality. Cronbach’s alpha for the total scale was 0.75. 
 
Preventive therapy decision 
Women were asked to indicate which of seven statements applied to them with regard to their 
decision about using tamoxifen for preventive therapy. The options were: ‘I decided immediately 
that I did not want to take tamoxifen’, ‘After some thought, I decided that I did not want to take 
tamoxifen’, ‘I am still deciding if I want to take tamoxifen’, ‘I met with my GP to talk about 
tamoxifen, and I decided against it’, ‘I met with my GP to talk about tamoxifen, but they would not 
prescribe it’, ‘I have a prescription for tamoxifen from my GP’, and ‘I am currently taking tamoxifen’. 
Women were classified as initiating tamoxifen if they reported having a prescription for tamoxifen 
from their GP or were currently taking tamoxifen (11).  
 
Analysis 
The analysis plan was pre-registered (DOI 10.17605/OSF.IO/YE6D2). To establish potential bias 
among the sample retained at follow-up, women responding to the baseline questionnaire only 
were compared with respondents to the 3-month questionnaire with regard to objective and 
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perceived knowledge about tamoxifen, healthcare professional satisfaction, and information 
provision. T-tests and Pearson’s Chi-square test were used where appropriate. Differences in socio-
demographic and clinical factors between responders and non-responders to the baseline 
questionnaire have previously been reported, and no differences were observed (11).   
 
Measures were described using percentages (with 95% Confidence Intervals [CI]) and means (with 
Standard Deviations [SD]). A multivariable logistic regression model was used to identify factors 
associated with good objective knowledge of tamoxifen, defined as recognising all three major 
potential harms and the potential benefit. This model was adjusted for participant characteristics, 
information provision, healthcare professional satisfaction and subjective knowledge about 
tamoxifen. In a sensitivity analysis, the proportion of women who correctly identified the benefit 
and at least 2 out of the 3 potential harms associated with tamoxifen were classified as having good 
knowledge about tamoxifen.  
 
To identify the factors associated with higher subjective decisional quality, we used a multivariable 
linear regression model adjusted for the same factors previously described as well as objective 
knowledge about tamoxifen. Multivariable logistic regression was used to examine factors 
associated with preventive therapy uptake (yes vs. no). The likelihood of having missing data for 
each of the measures is likely to be associated with individual factors (e.g. education level) or the 
variable itself (e.g. avoidance of knowledge assessments). As such, the missing data would be missing 
at random or missing not at random. Missing data were deleted listwise when examining descriptive 
data and univariable associations, and pairwise when multivariable analyses were used. A value of P 






In total, 732 women were invited to complete a survey; 408 women (55.7%, 95% CI: 52.1-59.4) 
returned the baseline survey and 258 (63.2%, 95% CI: 58.4-67.9) women provided uptake data at 
least 3 months after their appointment. 
 
Participant characteristics, clinical information and descriptions of the measures are presented in 
Table 1 and 2. The mean age of baseline respondents was 45.3 years (SD± 7.82). The majority of 
women had children, were married or cohabiting, had attained less than a degree level of education, 
correctly answered the numeracy item, were white, had good or excellent health, and were 
employed. The sample included more women who were classified as having a ‘moderately high’ risk 
of breast cancer than a ‘high’ risk of breast cancer. Patient satisfaction with healthcare professionals 
was high (mean=19.30, SD ± 3.77 out of 24). 
 
There were no differences between women who provided baseline data only and those who were 
retained at 3-month follow-up with regards to objective knowledge, healthcare professional 
satisfaction, and information provision (Table S1). A higher proportion of women who provided 
baseline and 3-month data felt informed about tamoxifen following their appointment in secondary 
care (91.0%, 95% CI: 86.8-94.2) compared with women who provided baseline data only (80.3%, 95% 
CI: 72.9-86.4). 
 
Knowledge about tamoxifen harms and benefits and information provision 
The majority of women reported feeling informed about tamoxifen and its use by women at 
increased risk of breast cancer following their appointment in secondary care (87.1%; 95% CI: 83.4-
90.2). However, in the objective assessment, only 15.7% (95% CI: 12.2-19.7) of women correctly 
identified the potential benefit (breast cancer risk reduction) and all three potential harms 
(endometrial cancer, menopausal symptoms, blood clotting) of using tamoxifen. Overall, 60.9% (95% 
12 
 
CI: 55.8-65.7) of women were aware tamoxifen could reduce breast cancer risk. Half of the sample 
were aware women taking tamoxifen were more likely to experience menopausal symptoms (50.1%; 
95% CI: 45.1-55.2) and blood clotting (49.7%; 95% CI: 44.7-54.8), and 27.3% (95% CI: 22.9-32.0) had 
knowledge about the increased risk of endometrial cancer associated with tamoxifen. A fifth (18.2%; 
95% CI: 14.5-22.4) of women recognised all three potential harms associated with taking tamoxifen.  
 
In a multivariable analysis, women with a higher level of education (odds ratio (OR)=2.24, 95% CI: 
1.11–4.55, p = 0.025) and with higher numeracy levels (OR=5.91, 95% CI: 1.33-26.19, p = 0.019) were 
more likely to have good knowledge about the potential benefits and harms of tamoxifen (Table 3).  
A registered sensitivity analyses changing the threshold for ‘good knowledge’, and an exploratory 
analysis re-classifying those with missing data as having incorrect knowledge, did not affect these 
estimates (Table S2 and Table S3, Supplementary Appendix).  
 
In total, 71.1% (95% CI: 66.4-75.4) of women stated their healthcare professional gave them a leaflet 
about tamoxifen during their appointment, with 28.9% (95% CI: 24.6-33.6) of women reporting that 
they did not receive or were unsure whether they received a leaflet. A higher proportion of women 
who received a leaflet about tamoxifen had good knowledge on its harms and benefits (17.9%), 
compared with those who did not receive a leaflet or were unsure (10.1%). In the multivariable 
analysis (Table 3), this difference was not statistically significant (OR=1.54, 95% CI: 0.66 – 3.59, p = 
0.313). 
 
Subjective decisional quality  
Among women who were followed-up at 3 months (n=258), 257 completed the decisional quality 
scale. Of this group, 111 (43.2%; 95% CI: 37.1-49.5) stated they were still deciding about tamoxifen 
(on ≥ 1 item) and 146 (56.8%; 95% CI: 50.5-62.9) had made their decision regarding tamoxifen. We 
conducted an exploratory analysis to examine the factors associated with women reporting they 
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were still deciding about tamoxifen on one or more items on the subjective decision quality scale 
(Table S4). In the multivariable analysis, women who felt more informed about tamoxifen were less 
likely to be still deciding about tamoxifen at 3-months (OR=0.88, 95% CI: 0.81-0.96, p = 0.003). 
 
Overall, among women who reported making a decision, there was a high level of decisional quality 
about tamoxifen, with a mean ± SD score of 17.03 ± 1.87 out of a possible 18. Most women reported 
having no regret about their decision (92.5%; 95% CI: 88.2, 96.8; 135/146), having the right amount 
of involvement in their decision (93.8%; 95% CI: 89.9, 97.7; 137/146), felt enough information was 
provided (90.4%; 95% CI: 85.6, 95.2; 132/146), and had the right amount of time to make a decision 
(95.9%; 95% CI: 92.7, 99.1; 140/146). Endorsement was lower for whether the decision was 
‘completely right for me’ (78.1%; 95% CI: 71.4, 84.8; 114/146), and for feeling totally satisfied with 
their decision (77.4%; 95% CI: 70.6, 84.2; 113/146). 
 
In a multivariable model including women who had reached a decision about tamoxifen initiation 
(n=128), those who felt more informed about tamoxifen after their appointment in secondary care 
(vs. less informed) (β = 0.22, p = 0.018) and who were from more disadvantaged socioeconomic 
backgrounds (vs. least deprived) (β = 0.27, p = 0.015) reported higher decisional quality (Table 4) 
(n=18 missing data). 
 
Factors associated with uptake of tamoxifen 
Responses to the uptake items included: ‘I decided immediately that I did not want to take 
tamoxifen’ (20.5% [95% CI: 15.8-26.0], 53/258), ‘After some thought, I decided that I did not want to 
take tamoxifen’ (29.8% [95% CI: 24.3-35.8], 77/258), ‘I am still deciding if I want to take tamoxifen’ 
(30.6% [95% CI: 25.1-36.6], 79/258), ‘I met with my GP to talk about tamoxifen, and I decided against 
it’ (3.5% [95% CI: 1.6-6.5], 9/258), ‘I met with my GP to talk about tamoxifen, but they will not 
prescribe it’ (0%, 0/258), ‘I have a prescription for tamoxifen from my GP’ (2.7% [95% CI: 1.1-5.5], 
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7/258), and ‘I am currently taking tamoxifen’ (12.0% [95% CI: 8.3-16.6], 31/258). Two women did not 
provide a yes response to any item. Uptake of tamoxifen at 3 month follow-up was 14.7% (95% CI: 
10.6-19.7, 38/258) when combining responses from women with a prescription and who reported 
currently using tamoxifen.  
 
A higher proportion of women with good objective knowledge about the potential benefits and 
harms of using tamoxifen initiated chemoprevention (27.9%; 95% CI: 15.3-43.7, 12/43), compared 
with those with poor knowledge (12.2%; 95% CI: 8.00-17.5, 25/205) (Table 5). There were no 
statistically significant associations in the multivariable model (Table 5). Despite greater knowledge 
among women using tamoxifen compared with non-users, levels were not optimal: 65.8%, 95% CI: 
48.6-80.4 (25/38) of this group failed to recognise the major potential benefit and three major 
potential harms of the drug.   
 
Discussion 
In this multi-centre survey of healthy women considering breast cancer primary prevention, only 1 in 
6 women recognised the potential benefits and harms of tamoxifen, i.e. that it can reduce breast 
cancer risk, but may cause thromboembolic events, endometrial cancer and menopausal side-
effects. A third of women in this sample did not recognise any of these harms. Knowledge was 
particularly poor among women with lower levels of education and numeracy. Knowledge was 
higher among women who reported tamoxifen use at follow-up, but even among this group two 
thirds failed to recognise the key benefit and all three harms. Women’s decisions regarding breast 
cancer preventive therapy appear to be based on incomplete information, and this may be a 
particular problem for those with low literacy and numeracy skills.  
 
The finding of poor knowledge among users of tamoxifen may be problematic from a safety 
perspective. A lower level of awareness of these potential harms may hinder recognition of an 
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adverse event and delay or prevent help-seeking behaviour. Healthcare professionals counselling 
women who are initiating tamoxifen for primary prevention should promote awareness of these 
signs and symptoms during the counselling process. This should be presented using absolute risk 
information so patients are aware these harms are possible, but can accurately gauge the likelihood 
of experiencing them. If GPs are to initiate tamoxifen prescriptions, or continue those that have 
been started in secondary care, they are likely to require information and support. A recent national 
survey of GPs indicated nearly 60% felt uncomfortable discussing the harms and benefits of 
tamoxifen for primary prevention (16), although this study was conducted prior to its being licensed 
for this indication, in November 2018. Low knowledge among women initiating preventive therapy 
may also have detrimental effects on long-term adherence to the medication (29), which has been 
shown to be problematic in this context (8,30).   
 
As part of their discussion about tamoxifen, a substantial minority of women did not report receiving 
written information during their appointment. Clinical centres should make efforts to improve 
dissemination to ensure all women considering preventive therapy are provided with written 
informational support. However, improvements may be needed to the information currently being 
provided, as receipt of information may not substantially affect women’s knowledge of tamoxifen’s 
harms and benefits. This may be because the information was overly complex, which is supported by 
the observation that women with lower levels of education and numeracy had poorer knowledge. 
NICE decision tools are freely available (4). While these aids frame numerical information using 
evidence-based approaches (31), they are lengthy documents that contain complex terminology. 
These aids should be user-tested with the appropriate groups to ensure comprehension and 
usability (32,33). Alternative risk communication tools, such as interactive websites and ‘gist-based 
information’, have been shown to be acceptable to patients (33–35), and can improve breast cancer 
risk perceptions, knowledge and interest in using chemoprevention (36,37). Developing similar tools 




The data presented here highlight a gap between participants’ perceived and actual levels of 
knowledge about tamoxifen. The low levels of objective knowledge reported were not reflected in 
women’s judgements about their own awareness, with nearly all respondents indicating that they 
felt quite or very informed about tamoxifen after their appointment in secondary care. Weak 
associations between subjective and objective knowledge measures have previously been reported 
(21). Furthermore, objective knowledge did not affect subjective decisional quality, with average 
scores for this construct being notably high. The high levels of subjective decisional quality suggest 
that most women felt supported and involved in their decision about chemoprevention, and were 
satisfied with their choice. While there are no ‘correct’ responses to subjective decision quality 
scales (20), our data indicate women may be unaware of gaps in their knowledge, and as a result 
believe their decisions to be of high quality. Healthcare professionals should be aware that 
subjective assessments of knowledge and decisional quality may not reflect their own 
interpretations of a high quality decision in the preventive therapy setting. Clinicians may also need 
to go beyond simple checks of comprehension, and instead use techniques such as the ‘teach back’ 
method to verify understanding in verbal consultations (38,39). This involves the patient reporting 
back to the communicator their interpretation of the message conveyed, with misunderstandings 
addressed and clarified. Such measures could enhance the quality of informed decision making 
about tamoxifen chemoprevention for women at increased risk of developing breast cancer, even if 
uptake did not increase. 
 
This study had limitations. While response rates were high, and there were few differences among 
responders and non-responders, those who did not complete the questionnaires may have scored 
differently on the assessments. The proportion of women using tamoxifen was small, and therefore 
the confidence intervals for estimates involving this outcome were wide. These data were collected 
prior to the NICE 2017 updated guidelines recommending anastrozole for postmenopausal women, 
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and therefore our findings may not be generalisable to women considering this drug. The reliability 
of the subjective decision scale was below levels previously reported (20), and may have affected 
the associations reported. The study relied on self-reported uptake data, and therefore estimates 
may not be as reliable as more objective assessments. The proportion of women self-reporting use 
of tamoxifen at 3-months is likely to be falsely elevated due to a higher likelihood of drop-out among 
those less interested in the topic (e.g. non-users). In this study, women were followed up at 3 
months to investigate their decision about tamoxifen as this was decided to be a reasonable amount 
of time to consider the harms and benefits, and speak with a GP. However, data from the subjective 
decisional quality scale indicated approximately half of the sample were still considering whether to 
use tamoxifen. A longer follow-up may have affected the proportion of women currently using 
tamoxifen, and their responses to the decision quality scale. Furthermore, their decision to use 
breast cancer chemoprevention may have been influenced by discussions in primary care. 
Tamoxifen’s off-licence status has previously been identified as a barrier to GP prescribing for breast 
cancer prevention (16), and the data presented here were collected before this became a licensed 
indication by the MHRA in 2018. 
 
In conclusion, the majority of women at increased risk of breast cancer considering the use of 
tamoxifen for primary prevention reported low levels of knowledge in relation to its major potential 
benefit and harms. Knowledge was particularly poor among women with lower levels of education 
and numeracy, which has the potential to exacerbate socioeconomic inequalities. While information 
leaflets and support tools are available and appear to be provided to the majority of women faced 
with this decision, they do not appear to be effective at supporting adequate understanding of the 
potential harms and benefits. Objective knowledge was not associated with women’s subjective 
assessments of tamoxifen knowledge or decisional quality. Healthcare professionals should 
therefore be cautious about assuming an informed decision about breast cancer prevention has 
been made, and techniques such as the ‘teach back’ method could be usefully employed. There is 
18 
 
also scope for developing and testing decision aids about primary prevention of breast cancer using 
different formats and “gist” versus “verbatim” detail.  
19 
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TABLES AND FIGURES 
Table 1. Description of demographic and clinical data  
Mean (± SD) for continuous variables; % (95% CI) for categorical variables 
Baseline (n= 408)  n 
Age, mean ± SD 45.30 ± 7.82 408 
Children   
Yes 77.0 (72.6, 81.0) 314 
No 23.0 (19.0, 27.4) 94 
White ethnic group   
White 95.5 (93.0, 97.3) 384 
Other 4.5 (2.7, 7.0) 18 
Missing, n 6  
Education level   
Degree or above 44.2 (39.3, 49.3) 176 
Below degree level 55.8 (50.7, 60.7) 222 
Missing, n 10  
Health status   
Poor 4.0 (2.3, 6.4) 16 
Fair 19.5 (15.7, 23.7) 78 
Good 60.0 (55.0, 64.8) 240 
Excellent 16.5 (13.0, 20.5) 66 
Missing, n 8  
Risk level   
Moderate 59.6 (54.6, 64.4) 243 
High 39.0 (34.2, 43.9) 159 
Unclear 1.5 (0.5, 3.2) 6 
SES   
Low (most deprived) 29.9 (25.5, 34.7) 120 
Middle 32.7 (28.1, 37.5) 131 
High (least deprived) 37.4 (32.7, 42.3) 150 
Missing, n 7  
Employment   
Full-time 85.3 (81.5, 88.6) 348 
All other employments 14.7 (11.4, 18.5) 60 
Marital status   
Married or cohabiting 74.3 (69.7, 78.5) 298 
Unmarried 25.7 (21.5, 30.3) 103 
Missing, n 7  
Numeracy   
Good numeracy 81.8 (77.6, 85.5) 323 
Poor numeracy 18.2 (14.5, 22.4) 72 
Missing, n 13  
Key: CI, Confidence Interval; SES, Socioeconomic status; SD, Standard deviation. 
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Table 2. Description of tamoxifen knowledge and psychological data  
Mean (± SD) for continuous variables; % (95% CI) for categorical variables 
Baseline (n= 408)  n 
Received a leaflet about tamoxifen   
Yes 71.1 (66.4, 75.4) 290 
No  25.7 (21.6, 30.3) 105 
Unsure 3.2 (1.7, 5.4) 13 
Knowledge   
Potential benefit and harms of using tamoxifen+   
Yes 15.7 (12.2, 19.7) 60 
No 84.3 (80.3, 87.8) 323 
Missing, n 25  
Tamoxifen can reduce breast cancer risk   
Yes 60.9 (55.8, 65.7) 238 
No 39.1 (34.3, 44.2) 153 
Missing, n 17  
Tamoxifen can increase risk of menopausal symptoms   
Yes 50.1 (45.1, 55.2) 197 
No 49.9 (44.8, 54.9) 196 
Missing, n 15  
Tamoxifen can increase risk of blood clotting   
Yes 49.7 (44.7, 54.8) 193 
No 50.3 (45.2, 55.3) 195 
Missing, n 20  
Tamoxifen can increase risk of endometrial cancer   
Yes 27.3 (22.9, 32.0) 107 
No 72.7 (68.0, 77.1) 285 
Missing, n 16  
Satisfaction with healthcare professional, mean ± SD 19.30 (3.77) 375 
Missing, n 33  
Felt informed about tamoxifen   
Yes 87.1 (83.4, 90.2) 351 
No 12.9 (9.8, 16.6) 52 
Missing, n 5  
Three month follow-up (n = 258)   
Subjective decisional quality, Mean ± SD   17.03 ± 1.87 146 
‘Still deciding’, n 111  
Missing, n 1  
Key: CI, Confidence Interval; SES, Socioeconomic status; SD, Standard deviation. 
+
= This variable included the potential benefit of tamoxifen (a reduction in breast cancer risk) and three potential harms of 




Table 3. Knowledge about the potential harms and benefits of tamoxifen by participant 
characteristics and univariable and multivariable logistic regression model (n=317) 
Good knowledge+ (%; N) Univariable Multivariable 
OR (95% CI) P-value OR (95% CI) P-value 
Age      
     ≤ 35 years 10.3 (4) 0.66 (0.20 – 2.11) 0.479 0.54 (0.11 – 2.61) 0.443 
     36 – 49 years 16.9 (41) 1.16 (0.61 – 2.21) 0.644 0.71 (0.31 – 1.62) 0.417 
     ≥ 50 years 14.9 (15) Ref  Ref  
Children       
     Yes 16.2 (48) 1.21 (0.61 – 2.40) 0.585 1.38 (0.54 – 3.56) 0.504 
     No 13.8 (12) Ref  Ref  
Ethnic group*      
     White 15.1 (55) - - - - 
     Other 28.6 (4) - - - - 
Education level      
     Degree or above 22.2 (38) 2.40 (1.36 – 4.25) 0.003 2.24 (1.11 – 4.55) 0.025 
     Below degree level 10.6 (22) Ref  Ref  
Health status      
     Poor* 20.0 (3) -  -   
     Fair 6.8 (5) 0.36 (0.12 – 1.13) 0.079 0.39 (0.11 – 1.41) 0.149 
     Good 18.3 (42) 1.12 (0.53 – 2.39) 0.764 1.13 (0.48 – 2.65) 0.777 
     Excellent 16.7 (10) Ref  Ref  
Risk level      
     Moderate 18.9 (43) 1.82 (0.99 – 3.33) 0.052 1.96 (0.95 – 4.04) 0.069 
     High  11.3 (17) Ref  Ref  
     Unclear* 0.0 (0) -  -  
SES      
     Low (most deprived) 14.3 (16) 0.83 (0.42 – 1.67) 0.606 0.97 (0.43 – 2.22) 0.945 
     Middle  15.0 (19) 0.88 (0.45 – 1.71) 0.704 0.87 (0.39 – 1.93) 0.734 
     High (least deprived) 16.7 (23) Ref  Ref  
Employment      
     Full-time 16.1 (53) Ref  Ref  
     All other employments 13.0 (7) 0.78 (0.33 – 1.81) 0.556 1.07 (0.42 – 2.74) 0.894 
Marital status      
     Married or cohabiting 16.3 (46) 1.16 (0.60 – 2.21) 0.662 0.99 (0.43 – 2.29) 0.985 
     Unmarried 14.4 (14) Ref  Ref  
Numeracy      
Good numeracy 19.0 (58) 7.72 (1.84 – 32.43) 0.005 5.91 (1.33 – 26.19) 0.019 
Poor numeracy 2.9 (2) Ref  Ref  
Received leaflet      
Yes 17.9 (49) 1.94 (0.97 – 3.89) 0.062 1.54 (0.66 – 3.59) 0.313 
No/unsure  10.1 (11) Ref  Ref  
Satisfaction with HCP       
Mean ± SD 19.34 ± 3.55 1.00 (0.93 – 1.09) 0.922 0.98 (0.90 – 1.07) 0.664 
Informed about tamoxifen      
Yes 17.4 (58) 4.85 (1.15 – 20.55) 0.032 5.36 (0.67 – 42.66) 0.113 
No 4.2 (2) Ref  Ref  
*category not included in univariable and multivariable analyses due to insufficient cases.
  +
= This variable included the 
potential benefit of tamoxifen (a reduction in breast cancer risk) and three potential harms of tamoxifen (increased risk of 
menopausal symptoms, blood clotting and endometrial cancer).   
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Table 4. Subjective decisional quality by participant characteristics and univariable and 
multivariable linear regression model (n = 128) 
Decisional quality (mean ± SD) 
 
Univariable   Multivariable  
B (SE) β P-value B (SE) β P-value 
Age        
     ≤ 35 years 16.41 ± 2.15 -0.26 (0.56) -0.04 0.652 0.17 (0.74) 0.03 0.816 
     36 – 49 years 17.24 ± 1.51 0.58 (0.39) 0.14 0.139 0.50 (0.48) 0.12 0.294 
     ≥ 50 years 16.67 ± 2.59 Ref - - Ref - - 
Children         
     Yes 17.13 ± 1.58 0.48 (0.37) 0.11 0.205 0.24 (0.52) 0.05 0.644 
     No 16.66 ± 2.66 Ref - - Ref - - 
Ethnic group        
     White 17.04 ± 1.89 0.20 (0.78) 0.02 0.796 0.73 (0.97) 0.07 0.451 
     Other 16.83 ± 1.33 Ref - - Ref - - 
Education level        
     Degree or above 17.08 ± 1.86 0.11 (0.31) 0.03 0.728 -0.21 (0.41) -0.05 0.604 
    Below degree level 16.97 ± 1.90 Ref - - Ref - - 
Health status        
     Poor 17.17 ± 0.98 0.13 (0.83) 0.01 0.871 0.18 (1.12) 0.02 0.876 
     Fair 16.19 ± 2.65 -0.84 (0.49) -0.17 0.091 -1.13 (0.58) -0.23 0.054 
     Good 17.28 ± 1.65 0.25 (0.39) 0.07 0.526 0.04 (0.46) 0.01 0.936 
     Excellent 17.03 ± 1.66 Ref - - Ref - - 
Risk level        
     Moderate 17.15 ± 1.41 0.38 (0.33) 0.10 0.248 0.25 (0.38) 0.06 0.515 
     High  16.77 ± 2.57 Ref - - Ref - - 
     Unclear† - -   -  - 
SES        
Low (most deprived) 17.36 ± 1.11 0.40 (0.41) 0.09 0.333 1.25 (0.51) 0.27 0.015 
     Middle  16.84 ± 2.28 -0.12 (0.36) -0.03 0.731 0.08 (0.42) 0.02 0.855 
 High (least deprived) 16.97 ± 1.84  Ref - - Ref - - 
Employment        
     Full-time 17.10 ± 1.90 0.48 (0.44) 0.09 0.281 0.60 (0.53) 0.11 0.258 
                      All other  16.62 ± 1.66 Ref - - Ref - - 
Marital status        
  Married or cohabiting 17.13 ± 1.57 0.53 (0.38) 0.12 0.169 0.41 (0.51) 0.09 0.418 
     Unmarried 16.60 ± 2.75 Ref - - Ref - - 
Numeracy        
Good numeracy 17.07 ± 1.80 0.37 (0.43) 0.07 0.389 0.42 (0.49) 0.08 0.393 
Poor numeracy 16.70 ± 2.29  Ref - - Ref - - 
Received leaflet        
Yes 17.13 ± 1.37 0.34 (0.34) 0.08 0.323 0.21 (0.42) 0.05 0.620 
No/unsure  16.79 ± 2.75 Ref - - Ref - - 
Satisfaction with HCP         
Mean ± SD - 0.02 (0.04) 0.03 0.729 -0.02 (0.05) -0.04 0.642 
Informed about tamoxifen        
Yes 17.13 ± 1.77 1.88 (0.67) 0.23 0.005 1.78 (0.74) 0.22 0.018 
No 15.25 ± 2.76 Ref - - Ref  - 
Knowledge - harms and benefits         
Yes 17.33 ± 1.41 0.37 (0.41) 0.08 0.365 0.23 (0.48) 0.04 0.640 
No 16.97 ± 1.99 Ref - - Ref   
†category not included in univariable and multivariable analyses due to insufficient cases. 
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Table 5. Uptake of tamoxifen by participant characteristics and univariable and multivariable 
logistic regression model (n = 187) 
 
Uptake of tamoxifen (N; %) Univariable Multivariable 
OR (95% CI) P-value OR (95% CI) P-value 
Age      
     ≤ 35 years† 1 (3.8) -  - - 
     36 – 49 years 29 (17.3) 1.46 (0.63 – 3.39) 0.378 1.31 (0.46 – 3.76) 0.617 
     ≥ 50 years 8 (12.5) Ref  Ref  
Children       
     Yes 36 (17.6) 5.43 (1.26 – 23.34) 0.023 3.71 (0.73 – 18.80) 0.113 
     No 2 (3.8) Ref  Ref  
Ethnic group†      
     White 37 (15) - - - - 
     Other 1 (11.1) Ref  Ref  
Education level      
     Degree or above 20 (17.2) 1.41 (0.71 – 2.82) 0.327 1.54 (0.61 – 3.89) 0.360 
     Below degree level 18 (12.9) Ref  Ref  
Health status      
     Poor† 0 - - - - 
     Fair 5 (10.6) 0.68 (0.20 – 2.32) 0.538 0.81 (0.19 – 3.56) 0.783 
     Good 25 (16.6) 1.13 (0.46 – 2.82) 0.787 1.28 (0.43 – 3.84) 0.661 
     Excellent 7 (14.9) Ref  Ref  
Risk level      
     Moderate 24 (15.1) 1.05 (0.52 – 2.15) 0.885 0.75 (0.32 – 1.77) 0.510 
     High  14 (14.4) Ref  Ref  
     Unclear† 0 -  - - 
SES      
     Low (most deprived) 7 (11.9) 0.78 (0.30 – 2.03) 0.613 1.57 (0.54 – 4.58) 0.412 
     Middle  14 (16.3) 1.13 (0.52 – 2.47) 0.759 1.66 (0.64 – 4.27) 0.296 
     High (least deprived) 16 (14.7) Ref  Ref  
Employment      
     Full-time 32 (14.5) Ref  Ref  
     All other employments 6 (16.2) 1.14 (0.44 – 2.96) 0.783 1.88 (0.62 – 5.68) 0.265 
Marital status      
     Married or cohabiting 33 (16.7) 2.16 (0.80 – 5.81) 0.127 1.64 (0.47 – 5.70) 0.435 
     Unmarried 5 (8.5) Ref  Ref  
Numeracy      
Good numeracy 32 (15.3) 1.37 (0.50 – 3.76) 0.536 1.21 (0.35 – 4.23) 0.765 
Poor numeracy 5 (11.6) Ref  Ref  
Received leaflet about tamoxifen      
Yes 28 (14.9) 1.05 (0.48 – 2.29) 0.903 0.62 (0.24 – 1.58) 0.314 
No/unsure  10 (14.3) Ref  Ref  
Satisfaction with HCP       
Mean ± SD 19.54 ± 3.34 1.02 (0.93 – 1.12) 0.689 1.06 (0.94 – 1.20) 0.349 
Felt informed about tamoxifen†      
Yes 38 (16.3) - - - - 
No 0 (0.0) Ref  Ref  
Knowledge - harms and benefits       
Yes 12 (27.9) 2.79 (1.27 – 6.12) 0.011 2.47 (0.94 – 6.54) 0.067 
No 25 (12.2) Ref  Ref  
†category not included in univariable and multivariable analyses due to insufficient cases. 
